AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Dianthus Therapeutics, Inc.
Video analysis: DNTH
All videosNo video analysis for this stock yet. Request one from our team.
News: DNTH
Dianthus Therapeutics, Inc. (DNTH) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Dianthus Therapeutics, Inc. (DNTH) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on September 1, 2026, to four newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).
Dianthus Therapeutics to Participate in Three Investor Conferences During September
NEW YORK and WALTHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in three investor conferences.
Alyeska Investment Group L.P. Has $14.68 Million Stock Position in Dianthus Therapeutics, Inc. $DNTH
Alyeska Investment Group L.P. increased its position in shares of Dianthus Therapeutics, Inc. (NASDAQ: DNTH) by 188.2% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 150,592 shares of the company's stock after buying an additional 98,345 shares during the
Dianthus Therapeutics: The C1s Shakeout Strengthens The Bull Case
Dianthus Therapeutics is building a neuromuscular franchise around claseprubart, differentiated by clinical profile and financial independence. DNTH holds ~$1.2B in cash and investments, supporting multiple late-stage programs and reducing funding event risk through 2030. Claseprubart's dosing convenience, pathway selectivity, and strong early data set it apart amid evolving competitive dynamics, especially after Sanofi's setback.
Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
Antwerp, Belgium, August 10, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) ("Agomab" or the "Company"), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that its Board of Directors has proposed the appointments of Marino Garcia and Naimish Patel, M.
California State Teachers Retirement System Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTH
California State Teachers Retirement System boosted its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ: DNTH) by 155.5% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 40,584 shares of the company's stock after buying an additional
Dimensional Fund Advisors LP Purchases 114,767 Shares of Dianthus Therapeutics, Inc. $DNTH
Dimensional Fund Advisors LP lifted its position in Dianthus Therapeutics, Inc. (NASDAQ: DNTH) by 54.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 325,440 shares of the company's stock after purchasing an additional 114,767 shares during the quarter. Dimensional Fund Advisors
